프라더 윌리 증후군(PWS) 시장 : 세계 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(주요 32 시장) - 2025-2035년

Global Prader-Willi Syndrome (PWS) Market Outlook

Thelansis's "Global Prader-Willi Syndrome (PWS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prader-Willi Syndrome treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Prader-Willi Syndrome (PWS) Overview

Prader-Willi syndrome (PWS) is a complex, multisystem neurodevelopmental and endocrine disorder fundamentally caused by the loss of function of imprinted genes on the paternally inherited chromosome 15 (15q11.2-q13), most commonly resulting from a paternal microdeletion or maternal uniparental disomy. The disease is clinically characterized by a highly distinct, biphasic developmental and nutritional trajectory. In the neonatal period, patients present with profound central hypotonia, poor suck reflex, and failure to thrive; however, during early childhood, this relentlessly transitions into severe hyperphagia-an insatiable, biologically driven hunger resulting from profound hypothalamic dysfunction. If left unchecked, this lack of satiety rapidly precipitates morbid obesity and catastrophic metabolic comorbidities, including type 2 diabetes and severe obstructive sleep apnea. The phenotypic spectrum is further complicated by characteristic behavioral and psychiatric challenges, mild-to-moderate intellectual disability, and multiple endocrinopathies, most notably hypogonadism and central growth hormone deficiency. The modern standard of care mandates rigorous, multidisciplinary intervention. While the early initiation of recombinant human growth hormone (rhGH) therapy is the established standard for significantly improving linear growth, body composition, and metabolic homeostasis, there are currently no approved pharmacological therapies to mitigate the underlying hyperphagia. Consequently, long-term survival and management continue to rely heavily on strict, lifelong environmental security-including locked access to food-and relentless caregiver supervision.

Key Highlights:

• PWS is a rare, lifelong, multisystem disorder driven by hypothalamic dysfunction, with a stable but gradually increasing diagnosed patient population in the US.
• The US prevalent population is estimated to grow from 13.9K in 2025 to 14.8K by 2035, reflecting a modest growth trajectory (0.6-0.7% CAGR) driven by improved diagnosis and survival.
• The disease is characterized by severe hyperphagia and obesity-related complications, representing the most critical unmet need due to the absence of approved targeted therapies.
• Increasing clinical focus on appetite-regulating and hypothalamic pathway-targeted therapies is expected to significantly transform the future treatment landscape.

Market Overview:

• The US PWS market is projected to expand from $559M in 2025 to $3.96B by 2035, reflecting a strong double-digit CAGR, primarily driven by late-stage pipeline therapies targeting hyperphagia.
• Current market revenues are largely supported by recombinant human growth hormone (rhGH) therapy, which addresses growth and metabolic aspects but not hyperphagia.
• Future market expansion will be highly dependent on successful commercialization of therapies targeting appetite dysregulation and improving long-term disease outcomes.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Harmony Biosciences Management, Inc.
• ConSynance Therapeutics
• Soleno Therapeutics, Inc.
• Bright Minds Biosciences Pty Ltd
• Aardvark Therapeutics, Inc.
• Pfizer
• Rhythm Pharmaceuticals, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)